The vote
Semax received a favorable recommendation.
On July 24, 2026, participating advisers voted 8 to 5, with one abstention, to recommend Semax related bulk drug substances for the Section 503A Bulks List.
The committee considered Semax free base and Semax acetate in the context of uses identified in FDA's meeting materials. The committee's favorable recommendation went against FDA staff's proposed position that the substances not be included.
Regulatory meaning
The vote concerns compounding eligibility.
A favorable committee vote means advisers recommended that FDA consider Semax for the 503A bulk drug substances pathway. It does not create an approved Semax drug, and it does not substitute for FDA review of a specific finished product.
The limits
What the Semax vote does not prove
- It does not prove that Semax is safe or effective for cognitive performance, focus, migraine, cerebral ischemia, or any other use.
- It does not approve any oral strip, injection, nasal product, or branded formulation.
- It does not immediately authorize routine 503A compounding.
- It does not remove FDA's published concern that safety information is limited and peptide impurities may create risk.
What to watch
FDA action is the next meaningful milestone.
FDA can accept, modify, or reject the committee's recommendation. Readers should watch the agency's official compounding pages for future status changes and should be skeptical of claims that Semax is now “FDA approved.”
Format education
Products and the vote are separate questions.
Neuvéra uses a portable, pre measured strip format. That product format was not evaluated or endorsed by the advisory committee. The committee considered bulk drug substances in the compounding framework.
Related Neuvéra routine
Focus and Clarity
A pre-measured strip format designed to fit a consistent daily routine. No mixing or measuring.
$99
First order: save 10%
View Focus and ClarityCommercial disclosure: Strips Over Needles may direct readers to products sold by Neuvéra. The committee vote discussed above did not evaluate or endorse this product.
Primary and independent reporting
Sources
- FDA: July 23 and 24, 2026 Pharmacy Compounding Advisory Committee meeting record
- FDA: Bulk drug substances that may present significant safety risks
- TIME: Overview of the committee decisions and debate
- ABC News: Six peptides recommended by FDA advisers
Published July 29, 2026. This article is educational and does not provide medical advice. Consult a qualified professional about personal health decisions.